13 nov
|
FORESEE
|
Madrid
Valencia, Spain Call4Entrepreneurs - The ColliderAbout the job CEO AUMMIS (The Collider Programme)CEO AUMMIS (The Collider Programme)AUMMIS | Stem-free Uterine Manipulator for Minimally Invasive SurgeryCEO & Co-Founder Opportunity |MedTech | Gynecologic OncologyLaparoscopic hysterectomy depends on a uterine manipulator, and almost every model on the market works by inserting a rigid stem into the uterus. Clinical evidence has linked these manipulators to a higher risk ofcancer recurrence, because the stem damages tissue, manipulates the tumor and can spread malignant cells. As a result, many oncology patients still undergo open surgery.AUMMISremoves the stem. Itsvacuum-assisted systemholds the cervix with interchangeable cups, so surgeons can mobilize the uterus in laparoscopic and robotic surgery without traumatizing tissue or touching the tumor. The project was born atFISABIOandUniversitat Jaume I, and is now looking for the CEO who will turn it into a company.Where AUMMIS stands todayFunctional prototype, with proof of concept completed on cadaveric bodies ( TRL 4 )Granted Spanish patent, withEPO and USapplications pending andfreedom to operateconfirmed in Europe and the USClassified as aClass IIa medical device~1.3 million hysterectomiesperformed worldwide every yearA market dominated bylarge surgical device playerswhose manipulators are mostly stem-based, a clear path tolicensing or strategic partnershipA defined roadmap toCE marking, withpilot clinical studies planned for 2027and a financial strategy combining non-dilutive funding and private investment€143K grant from the Valencian Innovation Agency (AVI), co-funded by the EU (ERDF), to advance development, validation and transfer of the deviceThe founding teamDr. J. Antonio Llueca Abella– Future CSO. A gynecologic oncology surgeon and Principal Clinical Investigator at FISABIO, he identified the problem in the operating room.By the end of the 4-month validation phase,
you will have:A definedbusiness model and partnering strategy : licensing, co-development or a path to direct salesAregulatory and clinical roadmapunder MDR, toward CE marking and FDAAfunding plan for the next 24 months, combining non-dilutive programmes and private investmentFirst conversations opened withmedical device manufacturers and distributorsAgreement with the founding team on thecompany structureand spin-off creationThe OfferSignificant co-founder equity stakeas CEO upon company incorporation€8,000 stipendduring the validation phase (4 monthly instalments of €2,000)Opportunity to access aparticipative loan of up to €75,000to finance the first phases of the projectThe Collider venture-building programme : mentors and specialists in medtech, IP, regulatory, go-to-market and fundraising, plus support with spin-off creationInternational exposurethrough The Collider ecosystem (4YFN, Mobile World Congress, corporate & investor networks)Two years of post-incorporation support, including in-kind services, community access and portfolio perksExpected start:February-March 2027What you bringPrevious founder or early-stage startup experienceProven track record in the medical device industry, in BD, product, regulatory or general management, ideally with surgical devices or disposablesHands-on experience moving a device through MDR/CEor running clinical studies. You know what it takes to go from prototype to first-in-human.A network in the medtech industry : manufacturers, distributors or strategic partnersExperience closing deals, such as licensing, partnerships or fundraising, including non-dilutive funding (EU, CDTI or similar)Ability to translate clinical evidence into a business casethat convinces partners, investors and regulators, working closely with surgeons and engineersEligible to work in Spainand fluent inSpanish and EnglishBackground in gynecology, oncology or minimally invasive and robotic surgery#J-18808-Ljbffr
📌 Ceo Aummis (The Collider Programme) (Madrid)
🏢 FORESEE
📍 Madrid